Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
UTHR Stock Forecast 2025-2026
$291.72
Current Price
$13.10B
Market Cap
Buy 9
Hold 6
Sell 0
Wall St Analyst Ratings
Distance to UTHR Price Targets
+74.8%
To High Target of $510.00
+37.1%
To Median Target of $400.00
+7.6%
To Low Target of $314.00
UTHR Price Momentum
+3.0%
1 Week Change
-5.8%
1 Month Change
-5.6%
1 Year Change
-17.3%
Year-to-Date Change
-30.2%
From 52W High of $417.82
+9.3%
From 52W Low of $266.98
📊 TOP ANALYST CALLS
Did UTHR Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if United Therapeutics is one of their latest high-conviction picks.
Latest UTHR Stock Price Targets & Analyst Predictions
Based on our analysis of 20 Wall Street analysts, UTHR has a bullish consensus with a median price target of $400.00 (ranging from $314.00 to $510.00). The overall analyst rating is Strong Buy (8.1/10). Currently trading at $291.72, the median forecast implies a 37.1% upside. This outlook is supported by 9 Buy, 6 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Tiago Fauth at Wells Fargo, suggesting a 7.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
UTHR Analyst Ratings
9
Buy
6
Hold
0
Sell
UTHR Price Target Range
Low
$314.00
Average
$400.00
High
$510.00
Current: $291.72
Latest UTHR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for UTHR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 11, 2025 | B of A Securities | Greg Harrison | Neutral | Maintains | $315.00 |
| Jun 2, 2025 | Cantor Fitzgerald | Olivia Brayer | Overweight | Initiates | $405.00 |
| May 5, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $425.00 |
| May 1, 2025 | Morgan Stanley | Terence Flynn | Equal-Weight | Maintains | $348.00 |
| May 1, 2025 | JP Morgan | Jessica Fye | Overweight | Maintains | $350.00 |
| Apr 25, 2025 | Wells Fargo | Tiago Fauth | Equal-Weight | Downgrade | $314.00 |
| Apr 21, 2025 | JP Morgan | Jessica Fye | Overweight | Maintains | $355.00 |
| Apr 21, 2025 | B of A Securities | Greg Harrison | Neutral | Upgrade | $314.00 |
| Feb 27, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $425.00 |
| Jan 8, 2025 | UBS | Ashwani Verma | Buy | Maintains | $475.00 |
| Nov 1, 2024 | Goldman Sachs | Chris Shibutani | Neutral | Maintains | $302.00 |
| Oct 31, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $425.00 |
| Oct 31, 2024 | Ladenburg Thalmann | Matthew Kaplan | Buy | Maintains | $344.00 |
| Oct 31, 2024 | Argus Research | Jasper Hellweg | Buy | Maintains | $400.00 |
| Oct 31, 2024 | Oppenheimer | Hartaj Singh | Outperform | Maintains | $600.00 |
| Oct 21, 2024 | TD Cowen | Joseph Thome | Buy | Maintains | $400.00 |
| Sep 23, 2024 | Jefferies | Eun Yang | Buy | Maintains | $432.00 |
| Aug 28, 2024 | Oppenheimer | Hartaj Singh | Outperform | Maintains | $575.00 |
| Aug 20, 2024 | Wells Fargo | Tiago Fauth | Overweight | Maintains | $380.00 |
| Aug 1, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $400.00 |
United Therapeutics Corporation (UTHR) Competitors
The following stocks are similar to United Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
UTHR
United Therapeutics
mkt cap
12.78B
United Therapeutics Corporation (UTHR) Financial Data
United Therapeutics Corporation has a market capitalization of $13.10B with a P/E ratio of 11.6x. The company generates $2.99B in trailing twelve-month revenue with a 40.4% profit margin.
Revenue growth is +17.2% quarter-over-quarter, while maintaining an operating margin of +48.3% and return on equity of +19.9%.
Valuation Metrics
Market Cap
$13.10B
Enterprise Value
$9.82B
P/E Ratio
11.6x
PEG Ratio
10.4x
Price/Sales
4.4x
Growth & Margins
Revenue Growth (YoY)
+17.2%
Gross Margin
+88.4%
Operating Margin
+48.3%
Net Margin
+40.4%
EPS Growth
+5.1%
Financial Health
Cash/Price Ratio
+25.2%
Current Ratio
5.5x
Debt/Equity
2.9x
ROE
+19.9%
ROA
+13.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
United Therapeutics Corporation (UTHR) Business Model
About United Therapeutics Corporation
What They Do
Biotechnology company developing innovative pharmaceutical products.
Business Model
The company focuses on developing and commercializing therapies for chronic and life-threatening conditions, particularly pulmonary arterial hypertension (PAH). It generates revenue through a portfolio of pharmaceutical products, including oral and inhaled treatments that enhance patient quality of life.
Additional Information
United Therapeutics is headquartered in Silver Spring, Maryland, and engages in drug research across various stages, from clinical trials to post-market analysis. The company is also investing in innovative technologies like organ manufacturing and regenerative medicine, indicating a commitment to future medical advancements.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
1,305
CEO
Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.
Country
United States
IPO Year
1999
Website
www.unither.comUnited Therapeutics Corporation (UTHR) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Insmed Stock Jumps 29% on Encouraging PAH Study Results
INSM eyes the next steps as TPIP hits all endpoints in the PAH study, setting the stage for late-stage trials and broader potential in lung disease.
Jun 11, 2025
By Zacks Equity Research
Analyst Blog
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Jun 10, 2025
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
United Therapeutics (UTHR) shares surged recently with above-average trading volume, and positive earnings estimate revisions may indicate potential further price increases.
Why It Matters
United Therapeutics' share surge and increased trading volume signal strong investor interest, while positive earnings revisions may indicate potential for further price growth.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
United Therapeutics stock fell significantly as Insmed's PAH data outperformed its Tyvaso product. United's PAH products make up over 90% of its revenue, facing competition from Liquidia's Yutrepia.
Why It Matters
United Therapeutics' stock decline signals concerns over its competitive position in the PAH market, heavily reliant on its products, amidst stronger rival data from Insmed and Liquidia's challenge.
Source: Seeking Alpha
Market Sentiment:
Negative
Quick Summary
United Therapeutics (UTHR) reported earnings 30 days ago; investors may want to monitor upcoming developments related to the stock's performance.
Why It Matters
Earnings reports can influence stock price and investor sentiment. Upcoming developments or guidance from United Therapeutics may affect future performance and investment decisions.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
United Therapeutics Corporation (NASDAQ: UTHR) will host its Q1 2025 Earnings Conference Call on April 30, 2025, at 9:00 AM ET, featuring key executives and industry analysts.
Why It Matters
The upcoming earnings call for United Therapeutics could reveal key financial performance insights, growth strategies, and market expectations, influencing stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
United Therapeutics Corporation reported Q1 2025 revenues of $794.4 million, a 17% increase from $677.7 million in Q1 2024, marking a record revenue quarter.
Why It Matters
United Therapeutics' 17% revenue growth signals strong performance and market demand, potentially boosting investor confidence and stock value.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
United Therapeutics (UTHR) reported Q3 earnings of $6.63 per share, surpassing the Zacks Consensus Estimate of $6.29 and up from $6.17 per share a year earlier.
Why It Matters
United Therapeutics' strong earnings beat signals robust financial health and growth, potentially boosting investor confidence and impacting stock performance positively.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About UTHR Stock
What is United Therapeutics Corporation's (UTHR) stock forecast for 2025?
Based on our analysis of 20 Wall Street analysts, United Therapeutics Corporation (UTHR) has a median price target of $400.00. The highest price target is $510.00 and the lowest is $314.00.
Is UTHR stock a good investment in 2025?
According to current analyst ratings, UTHR has 9 Buy ratings, 6 Hold ratings, and 0 Sell ratings. The stock is currently trading at $291.72. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for UTHR stock?
Wall Street analysts predict UTHR stock could reach $400.00 in the next 12 months. This represents a 37.1% increase from the current price of $291.72. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is United Therapeutics Corporation's business model?
The company focuses on developing and commercializing therapies for chronic and life-threatening conditions, particularly pulmonary arterial hypertension (PAH). It generates revenue through a portfolio of pharmaceutical products, including oral and inhaled treatments that enhance patient quality of life.
What is the highest forecasted price for UTHR United Therapeutics Corporation?
The highest price target for UTHR is $510.00 from at , which represents a 74.8% increase from the current price of $291.72.
What is the lowest forecasted price for UTHR United Therapeutics Corporation?
The lowest price target for UTHR is $314.00 from Tiago Fauth at Wells Fargo, which represents a 7.6% increase from the current price of $291.72.
What is the overall UTHR consensus from analysts for United Therapeutics Corporation?
The overall analyst consensus for UTHR is bullish. Out of 20 Wall Street analysts, 9 rate it as Buy, 6 as Hold, and 0 as Sell, with a median price target of $400.00.
How accurate are UTHR stock price projections?
Stock price projections, including those for United Therapeutics Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 19, 2025 1:45 PM UTC